Prothrombotic fibrin clot phenotype is associated with recurrent pulmonary embolism after discontinuation of anticoagulant therapy

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 37, Issue 2, 2017, Pages 365-373

  Zabczyk, Michal ^a   Plens, Krzysztof ^b   Wojtowicz, Wioletta ^c   Undas, Anetta ^a,d  

^a Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^b Krakow Cardiovascular Research Institute   (Poland)

^c CRACOW UNIVERSITY OF TECHNOLOGY   (Poland)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

fibrin; fibrinolysis; pulmonary embolism; recurrence; thrombosis

Indexed keywords

ANTICOAGULANT AGENT; D DIMER; FIBRINOGEN; THROMBIN; BIOLOGICAL MARKER; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOT LYSIS; DEEP VEIN THROMBOSIS; DISEASE PREDISPOSITION; EUGLOBULIN LYSIS TEST; FEMALE; FIBRIN CLOT; FIBRINOLYSIS; FOLLOW UP; GENETIC POLYMORPHISM; HOSPITAL PATIENT; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERMEABILITY; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING; TURBIDITY; AREA UNDER THE CURVE; BLOOD; BLOOD CLOTTING TEST; CHI SQUARE DISTRIBUTION; DRUG ADMINISTRATION; DRUG EFFECTS; KINETICS; METABOLISM; MULTIVARIATE ANALYSIS; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PULMONARY EMBOLISM; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

ADULT; ANTICOAGULANTS; AREA UNDER CURVE; BIOMARKERS; BLOOD COAGULATION TESTS; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; KINETICS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; RECURRENCE; RISK FACTORS; ROC CURVE; THROMBIN; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 85011032015     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.308253     Document Type: Article

References (27)

1. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost. 2005;3:1611-1617. doi: 10.1111/j.1538-7836.2005.01415.x.
2. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12:464-474. doi: 10.1038/nrcardio.2015.83.
3. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samama MM, Spannagl M; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98:756-764.
4. Konstantinides SV, Torbicki A, Agnelli G, et al.; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35:3033-69, 3069a. doi: 10.1093/eurheartj/ehu283.
5. Heit JA. Predicting the risk of venous thromboembolism recurrence. Am J Hematol. 2012;87(suppl 1):S63-S67. doi: 10.1002/ajh.23128.
6. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet. 2010;376:2032-2039. doi: 10.1016/ S0140-6736(10)60962-2.
7. Undas A, Arins RA. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2011;31:e88-e99. doi: 10.1161/ ATVBAHA.111.230631.
8. Undas A, Zawilska K, Ciesla-Dul M, Lehmann-Kopydłowska A, Skubiszak A, Ciepłuch K, Tracz W. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood. 2009;114:4272-4278. doi: 10.1182/blood-2009-05-222380.
9. Lisman T, de Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood. 2005;105:1102-1105. doi: 10.1182/blood-2004-08-3253.
10. Siudut J, Grela M, Wypasek E, Plens K, Undas A. Reduced plasma fibrin clot permeability and susceptibility to lysis are associated with increased risk of postthrombotic syndrome. J Thromb Haemost. 2016;14:784-793. doi: 10.1111/jth.13264.
11. Martinez MR, Cuker A, Mills AM, Crichlow A, Lightfoot RT, Chernysh IN, Nagaswami C, Weisel JW, Ischiropoulos H. Enhanced lysis and accelerated establishment of viscoelastic properties of fibrin clots are associated with pulmonary embolism. Am J Physiol Lung Cell Mol Physiol. 2014;306:L397-L404. doi: 10.1152/ajplung.00265.2013.
12. Lami D, Cellai AP, Antonucci E, Fiorillo C, Becatti M, Grifoni E, Cenci C, Marcucci R, Mannini L, Miniati M, Abbate R, Prisco D. Residual perfusion defects in patients with pulmonary embolism are related to impaired fibrinolytic capacity. Thromb Res. 2014;134:737-741. doi: 10.1016/j. thromres.2014.07.013.
13. Morris TA, Marsh JJ, Chiles PG, Auger WR, Fedullo PF, Woods VL Jr. Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med. 2006;173:1270-1275. doi: 10.1164/rccm.200506-916OC.
14. Undas A, Slowik A, Wolkow P, Szczudlik A, Tracz W. Fibrin clot properties in acute ischemic stroke: relation to neurological deficit. Thromb Res. 2010;125:357-361. doi: 10.1016/j.thromres.2009.11.013.
15. Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev. 2007;21:131-142. doi: 10.1016/j.blre.2006.11.001.
16. Traby L, Kollars M, Eischer L, Eichinger S, Kyrle PA. Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study. PLoS One. 2012;7:e51447. doi: 10.1371/journal.pone.0051447.
17. Meltzer ME, Bol L, Rosendaal FR, Lisman T, Cannegieter SC. Hypofibrinolysis as a risk factor for recurrent venous thrombosis; results of the LETS follow-up study. J Thromb Haemost. 2010;8:605-607. doi: 10.1111/j.1538-7836.2009.03715.x.
18. Goldhaber SZ. Risk factors for venous thromboembolism. J Am Coll Cardiol. 2010;56:1-7. doi: 10.1016/j.jacc.2010.01.057.
19. Eichinger S, Hron G, Kollars M, Kyrle PA. Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. Clin Chem. 2008;54:2042-2048. doi: 10.1373/clinchem.2008.112243.
20. Hemker HC, Al Dieri R, De Smedt E, Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006;96:553-561.
21. Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, Iotti M, Tormene D, Simioni P, Pagnan A. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92:199-205.
22. McRae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet. 2006;368:371-378. doi: 10.1016/S0140-6736(06)69110-1.
23. Tormene D, Ferri V, Carraro S, Simioni P. Gender and the risk of venous thromboembolism. Semin Thromb Hemost. 2011;37:193-198. doi: 10.1055/s-0031-1273083.
24. Limbrey R, Howard L. Developments in the management and treatment of pulmonary embolism. Eur Respir Rev. 2015;24:484-497. doi: 10.1183/16000617.00006614.
25. Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol. 2010;30:1672-1678. doi: 10.1161/ATVBAHA.109.198473.
26. Arins RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood. 2000;96:988-995.
27. Tritschler T, Méan M, Limacher A, Rodondi N, Aujesky D. Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model. Blood. 2015;126:1949-1951. doi: 10.1182/blood-2015-04-641225.